Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Functional Equivalence” Battle Has Just Begun, Sen. Hatch Aide Says

Executive Summary

Reimbursement for biologics will come under increased scrutiny with the passage of a Medicare drug benefit, Sen. Orrin Hatch's Legislative Assistant Bruce Artim predicts
Advertisement

Related Content

Medicare Bills Head To Conference: Senate Earns Broader Bipartisan Support
Medicare Bills Head To Conference: Senate Earns Broader Bipartisan Support
CMS “Functional Equivalence” Standard Targeted In Medicare Bills
Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Advertisement
UsernamePublicRestriction

Register

PS042085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel